HLA-G inhibits the process in which immune cells destroy tumor cells by binding to a multitude of receptors, such as KIRs, CD8, and leukocyte immunoglobulin like receptor sub family B member 1 (LIR 1), which are expressed on the surface of immune cells. Here, HLA-G is linked to neoplasm.